Tier 2 — strong

Effect of quercetin on CYP3A activity in Chinese healthy participants

Kai-Ming Duan, Sai-Ying Wang, Wen Ouyang, Yan-Mei Mao, Li-Jun Yang
Journal of clinical pharmacology 2012 52(6):940

Bibliography

PubMed
PMID 21680781
DOI
10.1177/0091270011406278
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized open-label two-period crossover interaction study
ModelHuman intervention research
Sample18 healthy men; 165 people genotyped during screening
InterventionQuercetin 500 mg/day for 13 days, then oral midazolam 7.5 mg
DurationTwo treatment periods with 24-hour probe-drug sampling
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2012, this source examined safety, interactions and special populations. Design: Randomized open-label two-period crossover interaction study. Sample/model: 18 healthy men; 165 people genotyped during screening. The exposure or intervention was Quercetin 500 mg/day for 13 days, then oral midazolam 7.5 mg. Follow-up or treatment period: Two treatment periods with 24-hour probe-drug sampling.

Midazolam exposure decreased in selected CYP3A5 genotype groups, consistent with increased probe-drug metabolism under this schedule.

The clinical sample was 18, not 165. Findings are genotype- and substrate-dependent and contradict a blanket claim that quercetin always inhibits CYP3A in humans.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Midazolam exposure decreased in selected CYP3A5 genotype groups, consistent with increased probe-drug metabolism under this schedule.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 500 mg/day for 13 days, then oral midazolam 7.5 mg; Two treatment periods with 24-hour probe-drug sampling.

What this study can and cannot tell us

  • The clinical sample was 18, not 165. Findings are genotype- and substrate-dependent and contradict a blanket claim that quercetin always inhibits CYP3A in humans.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology